Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3061-3061 ◽  
Author(s):  
T. Gil ◽  
P. Schöffski ◽  
A. Awada ◽  
H. Dumez ◽  
S. Bartholomeus ◽  
...  
Keyword(s):  
Single Dose ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Final Analysis ◽  
Advanced Solid Tumors ◽  
The Novel ◽  
Dose Escalation Study

A Phase I Dose–Escalation Study of Regorafenib (BAY 73–4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

2012 ◽  
Vol 18 (9) ◽  
pp. 2658-2667 ◽  
Author(s):  
Klaus Mross ◽  
Annette Frost ◽  
Simone Steinbild ◽  
Susanne Hedbom ◽  
Martin Büchert ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Sunitinib in combination with docetaxel in patients with advanced solid tumors: a phase I dose-escalation study

2009 ◽  
Vol 66 (4) ◽  
pp. 669-680 ◽  
Author(s):  
Francisco Robert ◽  
Alan Sandler ◽  
Joan H. Schiller ◽  
Glenn Liu ◽  
Karen Harper ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors

2014 ◽  
Vol 74 (5) ◽  
pp. 917-925 ◽  
Author(s):  
Carlos R. Becerra ◽  
Paul Conkling ◽  
Nicholas Vogelzang ◽  
Hilary Wu ◽  
Shengyan Hong ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Phase I Dose-Escalation Study of MEDI-573, a Bispecific, Antiligand Monoclonal Antibody against IGFI and IGFII, in Patients with Advanced Solid Tumors

2014 ◽  
Vol 20 (18) ◽  
pp. 4747-4757 ◽  
Author(s):  
Paul Haluska ◽  
Michael Menefee ◽  
Elizabeth R. Plimack ◽  
Jonathan Rosenberg ◽  
Donald Northfelt ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study

scholarly journals Phase I, First‐in‐Human, Dose‐Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Vorolanib in Patients with Advanced Solid Tumors

2018 ◽  
Vol 24 (4) ◽  
pp. 455 ◽  
Author(s):  
Johanna C. Bendell ◽  
Manish R. Patel ◽  
Kathleen N. Moore ◽  
Cynthia C. Chua ◽  
Hendrik‐Tobias Arkenau ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Advanced Solid Tumors ◽  
Dose Escalation Study ◽  
Human Dose
Sign in / Sign up

Export Citation Format

Share Document